antibody

BRCA1 Polyclonal Antibody

MBS125516

0.05 mg

230 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry, immunocytochemistry

Antibody

BRCA1 Polyclonal Antibody

BRCA1

BRCA1; BRCAI; BRCC1; BROVCA1; IRIS; PSCP; RNF53

Breast cancer type 1 susceptibility protein; Breast cancer type 1 susceptibility protein; breast cancer type 1 susceptibility protein; RING finger protein 53; Fanconi anemia, complementation group S; BRCA1/BRCA2-containing complex, subunit 1; protein phosphatase 1, regulatory subunit 53; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein 1; breast cancer 1, early onset; RING finger protein 53

BRCA1

BRCA1; BRCA1; IRIS; PSCP; BRCAI; BRCC1; FANCS; PNCA4; RNF53; BROVCA1; PPP1R53; RNF53

BRCA1_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

1863

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

WB: 1:500 - 1:2000. IHC: 1:50 - 1:200. IF: 1:50 - 1:200

Species: Human. Route: Synthetic Peptide

Immunogen: A synthetic peptide of human BRCA1. Calculated Molecular Weight: 208kDa

Polyclonal

The breast cancer susceptibility proteins BRCA1 and BRCA2 are frequently mutated in cases of hereditary breast and ovarian cancers and have roles in multiple processes related to DNA damage, repair, cell cycle progression, transcription, ubiquitination and apoptosis (1-4). BRCA2 has been shown to be required for localization of Rad51 to sites of double stranded breaks (DSBs) in DNA, and cells lacking BRCA1 and BRCA2 cannot repair DSBs through the Rad51-dependent process of homologous recombination (HR) (5). Numerous DNA-damage induced phosphorylation sites on BRCA1 have been identified, including serines 988, 1189, 1387, 1423, 1457, 1524 and 1542, and kinases activated in a cell cycle-dependent manner, including Aurora A and CDK2, can also phosphorylate BRCA1 at Ser308 and Ser1497, respectively (6-10). Cell cycle-dependent phosphorylation of BRCA2 at Ser3291 by CDKs has been proposed as a mechanism to switch off HR as cells progress beyond S-phase by blocking the carboxy-terminal Rad51 binding site (11).

728984

P38398.2

P38398

1863

ATF-2 Transcription Factor Network Pathway 138006!!ATM Mediated Phosphorylation Of Repair Proteins Pathway 105865!!ATM Mediated Response To DNA Double-strand Break Pathway 105864!!Androgen Receptor Signaling Pathway 198806!!Aurora A Signaling Pathway 137925!!BARD1 Signaling Events Pathway 137959!!BRCA1-associated Genome Surveillance Complex (BASC) Pathway 413428!!BRCA1-associated Genome Surveillance Complex (BASC) Pathway 890555!!Cell Cycle Pathway 530733!!Coregulation Of Androgen Receptor Activity Pathway 138085

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009]

0.05 mg

230 USD